TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce two significant updates aimed at advancing our mission and improving stakeholder engagement.
Dr. Lior Shaltiel, Chief Executive Officer of NurExone, will be presenting at the Emerging Growth Conference – Biotech Feature. This online conference is specifically tailored towards the healthcare sector and will start on July 18, 2024, at 9:00am ET. NurExone presentation is scheduled from 2:55pm to 3:25pm ET. This conference is a prime platform for emerging growth companies to showcase their latest advancements and strategic initiatives. Dr. Shaltiel’s presentation will focus on NurExone's groundbreaking ExoTherapy platform and its nanodrug ExoPTEN under development for acute spinal cord injuries. We invite all stakeholders, investors, and interested parties to join us for this presentation using this link.
In our continuous effort to improve communication, NurExone is proud to announce the launch of our newly updated website. The redesign aims to provide a clearer, more intuitive interface that makes it easier for collaborators, pharmaceutical companies, and other stakeholders to find the information they need. We believe these improvements will foster better engagement with our community and support our mission to develop cutting-edge exosome loaded therapies for central nervous system disease.
For more information, please visit our updated website at www.nurexone.com.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to Dr. Shaltiel’s proposed attendance and presentation at the conference; Dr. Shaltiel’s presentation focusing on NurExone's groundbreaking ExoTherapy platform and its nanodrug ExoPTEN under development for acute spinal cord injuries; the proposed conference and details thereof; the statement that the NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; the website and its benefits; and the Company’s ongoing commitment to using its ExoTherapy platform and nanodrug ExoPTEN to treat acute spinal cord injuries.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including Dr. Shaltiel’s presentation increasing the visibility of the Company and its technological developments; Dr. Shaltiel’s presentation on NurExone's groundbreaking ExoTherapy platform and its nanodrug ExoPTEN under development for acute spinal cord injuries; the Company’s ability to realize upon the stated potential for its nanodrug ExoPTEN to treat acute spinal cord injuries; the Company’s ability to realize the NurExone platform technology to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; the new website being more clear, intuitive, and easy to follow for collaborators, pharmaceutical companies, and other stakeholders; and the Company’s ability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to Dr. Shaltiel’s presentation not having its intended outcomes; Dr. Shaltiel not presenting on NurExone's groundbreaking ExoTherapy platform and its nanodrug ExoPTEN under development for acute spinal cord injuries; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; the fact that its nanodrug ExoPTEN is still under development; the fact that the effects of the nanodrug ExoPTEN are still uncertain; the potential inability to obtain or maintain regulatory approval of ExoPTEN; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the potential inability to obtain adequate financing; dependence on the Company’s strategic partners; the protection of the Company’s intellectual property; the potential inability to obtain or maintain intellectual property protection for the ExoTherapy platform and ExoPTEN; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the website not being more clear, intuitive, or easy to follow for collaborators, pharmaceutical companies, and other stakeholders; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
